Vardenafil (Levitra/Staxyn) in Adults 65 and Older: Off-Label Uses, Dosing, and Safety

What Is Vardenafil and Why Does Age Matter?

Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that works by amplifying cyclic GMP-mediated smooth-muscle relaxation in penile vasculature. The FDA approved Levitra (vardenafil HCl) in 2003 for ED in adult men, and Staxyn (vardenafil 10 mg orally disintegrating tablet) in 2010 [1]. Neither formulation carries a pediatric or geriatric-specific FDA approval for any other indication.

Age changes drug behavior significantly. A pharmacokinetic study cited in the Levitra prescribing information found that the area under the concentration-time curve (AUC) for vardenafil is about 40 percent higher and peak plasma concentration (Cmax) is about 34 percent higher in men aged 65 and older compared with men aged 18 to 45 [1]. Renal clearance declines with age. Hepatic CYP3A4 activity also falls, slowing metabolism.

Why Pharmacokinetics Shift After 65

Three physiological changes drive higher drug exposure in older adults.

First, body composition shifts toward lower lean mass and higher fat fraction, which increases the volume of distribution for lipophilic drugs. Vardenafil is moderately lipophilic (log P approximately 2.3).

Second, hepatic blood flow drops roughly 40 percent between age 25 and 75, reducing first-pass extraction of drugs with moderate hepatic extraction ratios [2]. Vardenafil is primarily cleared by CYP3A4 in the liver.

Third, plasma protein binding changes. Vardenafil is about 95 percent protein-bound. Age-related reductions in albumin can shift the free fraction upward, increasing pharmacodynamic effect at any given total drug level [1].

Practical Dose Implications

Because of these combined changes, the FDA-approved labeling specifies a starting dose of 5 mg in men aged 65 and older, compared with 10 mg in younger men [1]. The dose may be titrated to 10 mg based on efficacy and tolerability, but should not exceed 20 mg in any patient. Clinicians prescribing off-label in this age group should anchor to the same 5 mg starting point.

FDA-Approved Use: Erectile Dysfunction in Older Men

ED is common in men over 65. National Health and Nutrition Examination Survey data showed that the prevalence of moderate-to-complete ED exceeds 50 percent in men aged 60 to 69 and approaches 70 percent in men aged 70 and older [3]. Vardenafil has demonstrated efficacy across this age range in controlled trials.

Evidence in Men Over 65

A pre-specified subgroup analysis of the key vardenafil Phase 3 program examined 252 men aged 65 and older. Vardenafil 10 mg and 20 mg produced International Index of Erectile Function Erectile Function domain (IIEF-EF) scores that were significantly higher than placebo (P<0.001), and successful intercourse rates roughly doubled vs. Placebo [4]. The absolute improvement in IIEF-EF from baseline was 6.4 points with 10 mg, similar to the 7.1-point improvement seen in younger cohorts.

A Cochrane systematic review of PDE5 inhibitors for ED (which included 82 randomized controlled trials and over 17,000 participants) confirmed that all three approved agents (sildenafil, tadalafil, vardenafil) produced clinically meaningful improvements in IIEF-EF scores across all reported age subgroups, with no statistically significant interaction between age and treatment response [5].

What Changes Clinically at 65+

The drug still works. The caution is not about efficacy but about a wider safety margin between the therapeutic dose and the hypotensive threshold.

Older men are more likely to be taking alpha-blockers for BPH or antihypertensives for cardiovascular disease, both of which potentiate vardenafil's blood-pressure-lowering effect. The American Urological Association's ED guideline notes that the combination of a PDE5 inhibitor and an alpha-blocker should be used with caution, with the PDE5 inhibitor initiated at the lowest dose, and that the two drugs should not be started simultaneously [6].

Off-Label Uses in Patients 65 and Older

Lower Urinary Tract Symptoms

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) represent one of the more extensively studied off-label applications of PDE5 inhibitors in older men. PDE5 is expressed in the prostate, bladder neck, and urethra, providing a mechanistic rationale.

A 12-week randomized controlled trial published in the Journal of Urology (N=222, mean age 62) found that vardenafil 10 mg twice daily reduced total International Prostate Symptom Score (IPSS) by 5.9 points vs. 2.9 points with placebo (P<0.001) [7]. The benefit was additive when combined with tamsulosin. Although the mean age in that trial was below 65, the IPSS improvements held in the subgroup aged 65 and older.

It is worth distinguishing vardenafil from tadalafil here. Tadalafil 5 mg daily received FDA approval specifically for LUTS/BPH in 2011, making it the preferred first-line PDE5 inhibitor for that indication in guidelines. Vardenafil remains off-label for LUTS. Clinicians who prescribe it for this purpose are doing so outside labeling, which requires explicit informed consent documentation.

Raynaud Phenomenon

Raynaud phenomenon involves episodic vasospasm of digital vessels. PDE5 inhibitors cause vasodilation by the same cGMP mechanism that operates in penile and pulmonary vasculature. A randomized crossover trial of sildenafil vs. Placebo for secondary Raynaud published in Annals of the Rheumatic Diseases established PDE5 inhibition as a mechanistically valid approach [8]. Vardenafil has been used by some rheumatologists in patients who do not tolerate calcium channel blockers, the first-line agent.

No large controlled trial has validated vardenafil specifically in older adults with Raynaud. The off-label use is supported primarily by mechanism and case series. In patients over 65, the cardiovascular risk profile must be assessed carefully before initiation, because Raynaud in this age group is more often secondary (associated with systemic sclerosis or other autoimmune disease) and cardiovascular comorbidities are common.

Altitude Sickness and High-Altitude Pulmonary Edema

PDE5 inhibitors blunt hypoxic pulmonary vasoconstriction and reduce pulmonary artery pressure at altitude. Tadalafil 10 mg twice daily is recommended in the Wilderness Medical Society's altitude illness guidelines as prophylaxis for high-altitude pulmonary edema (HAPE) in high-risk individuals [9]. Sildenafil has a similar evidence base.

Vardenafil has been studied in this context. A small randomized double-blind trial (N=12) found that vardenafil 10 mg reduced exercise-induced pulmonary artery systolic pressure at 3,454 meters by approximately 6 mmHg compared with placebo [10]. The clinical relevance for a patient aged 65 traveling to high altitude (above 2,500 meters) is real, particularly if tadalafil or sildenafil is unavailable. However, the Wilderness Medical Society guideline does not yet specifically recommend vardenafil for this purpose, and dosing in older adults at altitude has not been separately studied.

Pulmonary Arterial Hypertension: A Distinction

FDA-approved treatments for pulmonary arterial hypertension (PAH) include sildenafil (Revatio) and tadalafil (Adcirca), not vardenafil. Using vardenafil for PAH in an older adult would be doubly off-label (both for the indication and for the formulation, since Levitra/Staxyn are not labeled for PAH). A 2010 randomized trial (N=66, mean age 48) did find that vardenafil 5 mg twice daily improved 6-minute walk distance by 69 meters over placebo at 16 weeks [11]. This is the foundational evidence clinicians cite for off-label use. In patients over 65 with PAH, however, approved agents with age-specific data are the standard of care.

Drug Interactions: A Magnified Risk in Older Patients

Polypharmacy is the rule, not the exception, in adults over 65. A 2019 analysis of Medicare Part D data found that 42 percent of adults aged 65 and older take five or more prescription drugs daily [12]. Each added drug multiplies the interaction surface for vardenafil.

Nitrates: Absolute Contraindication

Concurrent use of organic nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) is an absolute contraindication. The combination can cause severe, potentially fatal hypotension. This contraindication applies regardless of dose, route, or timing. The prescribing information states: "Administration of LEVITRA with nitrates or nitric oxide donors is contraindicated" [1].

Older men with coronary artery disease are frequently on long-acting nitrates. Any prescriber considering vardenafil in a patient over 65 must review the complete medication list for nitrate exposure, including transdermal patches and sublingual rescue formulations.

Alpha-Blockers

Alpha-blockers (tamsulosin, terazosin, doxazosin, alfuzosin) are widely prescribed for BPH in men over 65. Vardenafil combined with non-selective alpha-blockers (terazosin, doxazosin) can produce symptomatic orthostatic hypotension. The prescribing label recommends waiting at least 6 hours after a tamsulosin dose before taking vardenafil, and contraindicates same-day co-administration with doxazosin at doses above 4 mg [1].

CYP3A4 Inhibitors

Because vardenafil is metabolized almost entirely by CYP3A4, inhibitors of this enzyme raise vardenafil plasma concentrations substantially.

• Ketoconazole 200 mg raises vardenafil AUC by 10-fold. The maximum dose with ketoconazole 200 mg is 5 mg per 24 hours. With ketoconazole 400 mg, the maximum is 2.5 mg per 24 hours [1].
• Erythromycin raises vardenafil AUC by approximately 4-fold. Maximum dose: 5 mg per 24 hours [1].
• Ritonavir raises vardenafil AUC by 49-fold. Co-administration is contraindicated [1].
• Indinavir and other HIV protease inhibitors carry similar restrictions.

In an older patient already started at 5 mg because of age, the addition of a moderate CYP3A4 inhibitor may require further reduction to 2.5 mg or temporary discontinuation.

Cardiovascular Safety in Older Adults

Baseline Cardiovascular Assessment

The Princeton Consensus Guidelines (third edition) stratify men with ED by cardiovascular risk before PDE5 inhibitor prescribing. Low-risk patients (controlled hypertension, asymptomatic CAD, mild valvular disease) can proceed with PDE5 inhibitor treatment without further cardiac workup. Intermediate-risk patients require additional evaluation before prescribing. High-risk patients (unstable angina, decompensated heart failure, uncontrolled arrhythmia) should not receive PDE5 inhibitors until their cardiac status is stabilized [13].

Adults over 65 are disproportionately represented in the intermediate and high-risk categories. The clinical review at the time of prescribing should include current functional capacity (can the patient exert 3 to 4 metabolic equivalents without symptoms?), blood pressure, and current medication list.

Hypotension Risk Profile

Vardenafil alone lowers mean supine systolic blood pressure by approximately 6 mmHg and diastolic by 4 mmHg, based on placebo-subtracted data from the key trials [1]. This effect is modest in healthy younger adults but can be clinically significant in older patients with baseline autonomic dysfunction, volume depletion, or antihypertensive medication burden.

Clinicians should advise patients to change positions slowly after taking vardenafil, particularly the first few doses.

QTc Prolongation

Vardenafil produces a small but measurable prolongation of the QTc interval. A thorough QT study showed that vardenafil 10 mg extended mean QTcB by 8 msec and at the supratherapeutic dose of 80 mg extended it by 10 msec [1]. This is a concern in older patients who may already be taking QTc-prolonging drugs (certain antiarrhythmics, macrolides, fluoroquinolones, antipsychotics). A baseline ECG is reasonable before off-label initiation in patients over 65 with known cardiac conduction disease.

Hepatic and Renal Considerations After 65

Hepatic Impairment

Mild hepatic impairment (Child-Pugh class A) does not require dose adjustment. In moderate impairment (Child-Pugh class B), the maximum recommended dose is 5 mg, and the maximum dose per 24-hour period is 10 mg [1]. Severe hepatic impairment (Child-Pugh class C) is a contraindication.

Older adults with alcoholic liver disease, non-alcoholic steatohepatitis, or hepatitis-related cirrhosis require careful Child-Pugh scoring before prescription.

Renal Impairment

Renal impairment does not significantly alter vardenafil pharmacokinetics, because less than 0.1 percent of the administered dose is excreted unchanged in urine [1]. Dose adjustments are not required for mild-to-severe renal impairment or for patients on hemodialysis. This is a meaningful advantage over some other agents in older patients with chronic kidney disease.

Monitoring and Follow-Up Recommendations for Older Patients

The following framework applies to off-label vardenafil prescribing in patients aged 65 and older. It synthesizes current FDA labeling, the Princeton Consensus recommendations, and American Urological Association guidance into a practical checklist format.

Before the first prescription:

1. Confirm no current or recent nitrate use (within 24 hours for short-acting agents).
2. Review complete medication list for alpha-blockers and CYP3A4 inhibitors.
3. Assign Princeton cardiovascular risk tier. Do not prescribe in high-risk patients.
4. Obtain resting blood pressure. Hold if systolic is below 90 mmHg or above 170 mmHg.
5. Review hepatic function if clinical signs of liver disease are present.
6. Discuss the off-label nature of the prescription if the indication is not ED. Document informed consent.

At follow-up (4 to 8 weeks after initiation):

1. Ask about orthostatic symptoms, especially after the first few doses.
2. Re-measure blood pressure if the patient's antihypertensive regimen changed.
3. Review for new medications that might represent CYP3A4 inhibitors or nitrates.
4. Assess efficacy for the target indication using a validated instrument (IIEF-EF for ED, IPSS for LUTS).

Informed Consent Requirements for Off-Label Prescribing

The FDA explicitly permits off-label prescribing by licensed physicians, but the agency does not regulate the physician-patient relationship. Several state medical boards and institutional policies require documented informed consent when a drug is used outside its labeled indication, particularly in vulnerable populations.

For vardenafil off-label use in patients over 65, the documentation should include:

• The indication being treated.
• The fact that vardenafil is not FDA-approved for that indication.
• The known and potential risks in this age group.
• Alternative approved treatments (e.g., tadalafil for LUTS/BPH, nifedipine for Raynaud, tadalafil for PAH).
• The patient's acknowledgment that they understand the off-label nature of treatment.

The American Medical Association's Code of Medical Ethics Opinion 1.2.11 states that physicians have the responsibility to provide patients with accurate information about treatment options, including unapproved uses, in terms the patient can understand [14].

Comparing Vardenafil to Other PDE5 Inhibitors in Older Adults

Sildenafil, tadalafil, avanafil, and vardenafil differ in ways that matter at age 65 and above.

Tadalafil has a 17.5-hour half-life (vs. 4 to 5 hours for vardenafil), allowing for once-daily dosing at 5 mg. Steady-state plasma concentrations allow lower peak exposures, which may reduce the intensity of blood pressure effects after each dose. Tadalafil is also FDA-approved for LUTS/BPH, removing the off-label complexity for that indication.

Sildenafil is more sensitive to food interactions (a high-fat meal reduces Cmax by up to 29 percent). Vardenafil shows a similar, though slightly smaller, food effect. Neither effect is clinically decisive in most patients.

Avanafil has a faster onset (approximately 15 minutes) and shorter duration. It is less extensively studied in patients over 65 than either sildenafil or vardenafil.

Vardenafil's niche in older patients may be its relatively well-characterized pharmacokinetic profile in the elderly, its flexibility in tablet dosing, and the existence of the orally disintegrating Staxyn formulation for patients who have difficulty swallowing. The Staxyn formulation achieves higher Cmax than the equivalent Levitra tablet dose and is not bioequivalent to Levitra 10 mg [1]. That distinction matters when titrating.